Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

@article{Smith2008MetabolicCD,
  title={Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.},
  author={Matthew Raymond Smith and Hang Mei Lee and Francis J McGovern and Mary Anne Fallon and Melissa Goode and Anthony Laurence Zietman and Joel S. Finkelstein},
  journal={Cancer},
  year={2008},
  volume={112 10},
  pages={2188-94}
}
BACKGROUND In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome. To the authors' knowledge, however, less is known regarding the effects of GnRH agonists on other attributes of the metabolic syndrome. METHODS In an open-label prospective study, 26 men with recurrent or locally advanced prostate cancer were treated with leuprolide for 12 months… CONTINUE READING